Abstract
Aim. To evaluate the effects of canrenone compared to placebo on blood pressure control, some non-conventional biomarkers in cardiovascular stratification, and on metalloproteinases in patients affected by metabolic syndrome. Methods. A total of 156 Caucasian patients were treated with placebo or canrenone, 50 mg once a day, for 3 months and then 50 mg twice a day, till the end of the study. We evaluated: systolic (SBP) and diastolic blood pressure (DBP), body weight, body mass index (BMI), fasting plasma glucose (FPG), lipid profile, plasma aldosterone, creatinine, potassium, brain natriuretic peptide (BNP), metalloproteinases 2 and 9 (MMP-2 and -9), lipoprotein (a) (Lp(a)), and serum myeloperoxidase (MPO). Results. We observed a significant decrease of SBP and DBP in the canrenone group compared to baseline. Canrenone gave a significant decrease of MMP-2 and -9, Lp(a), and MPO compared to baseline, not observed with placebo. Plasma aldosterone, but not BNP, decreased with canrenone, both compared to baseline and to placebo. Conclusion. Canrenone seems to be effective in reducing blood pressure in patients with metabolic syndrome. Moreover, canrenone seems also to improve MPO, Lp(a), and metalloproteinases in these patients.
| Original language | English |
|---|---|
| Pages (from-to) | 47-52 |
| Number of pages | 6 |
| Journal | Annals of Medicine |
| Volume | 47 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Feb 1 2015 |
Fingerprint
Keywords
- Canrenone
- Inflammatory markers
- Metalloproteinases
ASJC Scopus subject areas
- Medicine(all)
Cite this
The effects of canrenone on inflammatory markers in patients with metabolic syndrome. / Derosa, Giuseppe; Romano, Davide; Bianchi, Lucio; D'angelo, Angela; Maffioli, Pamela.
In: Annals of Medicine, Vol. 47, No. 1, 01.02.2015, p. 47-52.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The effects of canrenone on inflammatory markers in patients with metabolic syndrome
AU - Derosa, Giuseppe
AU - Romano, Davide
AU - Bianchi, Lucio
AU - D'angelo, Angela
AU - Maffioli, Pamela
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Aim. To evaluate the effects of canrenone compared to placebo on blood pressure control, some non-conventional biomarkers in cardiovascular stratification, and on metalloproteinases in patients affected by metabolic syndrome. Methods. A total of 156 Caucasian patients were treated with placebo or canrenone, 50 mg once a day, for 3 months and then 50 mg twice a day, till the end of the study. We evaluated: systolic (SBP) and diastolic blood pressure (DBP), body weight, body mass index (BMI), fasting plasma glucose (FPG), lipid profile, plasma aldosterone, creatinine, potassium, brain natriuretic peptide (BNP), metalloproteinases 2 and 9 (MMP-2 and -9), lipoprotein (a) (Lp(a)), and serum myeloperoxidase (MPO). Results. We observed a significant decrease of SBP and DBP in the canrenone group compared to baseline. Canrenone gave a significant decrease of MMP-2 and -9, Lp(a), and MPO compared to baseline, not observed with placebo. Plasma aldosterone, but not BNP, decreased with canrenone, both compared to baseline and to placebo. Conclusion. Canrenone seems to be effective in reducing blood pressure in patients with metabolic syndrome. Moreover, canrenone seems also to improve MPO, Lp(a), and metalloproteinases in these patients.
AB - Aim. To evaluate the effects of canrenone compared to placebo on blood pressure control, some non-conventional biomarkers in cardiovascular stratification, and on metalloproteinases in patients affected by metabolic syndrome. Methods. A total of 156 Caucasian patients were treated with placebo or canrenone, 50 mg once a day, for 3 months and then 50 mg twice a day, till the end of the study. We evaluated: systolic (SBP) and diastolic blood pressure (DBP), body weight, body mass index (BMI), fasting plasma glucose (FPG), lipid profile, plasma aldosterone, creatinine, potassium, brain natriuretic peptide (BNP), metalloproteinases 2 and 9 (MMP-2 and -9), lipoprotein (a) (Lp(a)), and serum myeloperoxidase (MPO). Results. We observed a significant decrease of SBP and DBP in the canrenone group compared to baseline. Canrenone gave a significant decrease of MMP-2 and -9, Lp(a), and MPO compared to baseline, not observed with placebo. Plasma aldosterone, but not BNP, decreased with canrenone, both compared to baseline and to placebo. Conclusion. Canrenone seems to be effective in reducing blood pressure in patients with metabolic syndrome. Moreover, canrenone seems also to improve MPO, Lp(a), and metalloproteinases in these patients.
KW - Canrenone
KW - Inflammatory markers
KW - Metalloproteinases
UR - http://www.scopus.com/inward/record.url?scp=84923310377&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84923310377&partnerID=8YFLogxK
U2 - 10.3109/07853890.2014.969303
DO - 10.3109/07853890.2014.969303
M3 - Article
C2 - 25319120
AN - SCOPUS:84923310377
VL - 47
SP - 47
EP - 52
JO - Annals of Medicine
JF - Annals of Medicine
SN - 0785-3890
IS - 1
ER -